Tempus AI beats top-line and bottom-line estimates; raises FY26 outlook
Tempus AI reported Q3 earnings with non-GAAP EPS of $0.07, beating estimates by $0.15. Revenue reached $411.5M, up 23.1% year-over-year, exceeding expectations by $2.2M. Adjusted EBITDA grew to $25.6M from $1.5M in the same quarter last year. The company also raised its FY26 outlook.
How this was made
The 30-second read
Why it matters
The earnings beat reinforces the company's growth narrative, potentially attracting growth‑oriented investors.
Market read
The surprise earnings and raised outlook make TEM a short‑term buying candidate for traders focused on AI‑healthcare stocks.
What to watch
Guidance details are sparse; future cash‑burn and competition could temper upside.
Background
Tempus AI is a data‑driven precision medicine company that provides AI‑based analytics for oncology and other diseases.
Ticker impact
Tempus AI reported Q3 revenue of $411.5M (+23.1% YoY) beating estimates and non‑GAAP EPS of $0.07 beating by $0.15, while raising its FY26 outlook.
likely upward as investors price in the earnings beat and outlook raise
The surprise revenue and EPS beat, plus upgraded guidance, typically drive buying pressure on the stock.
Market effects
Positive earnings may lift other AI‑driven healthcare analytics firms.
Minor impact on US tech/healthcare sector indices.
Limited to investors tracking AI and health‑tech stocks.
Counterpoint
If the beat is already priced in, the stock could face short‑covering pull‑back.
Key entities
- companyTempus AI, Inc.
Provider of AI‑driven precision medicine analytics.
